Investments, Funding & Disinvestment

The transaction marks the end of Pfizer’s involvement with ViiV Healthcare, as the American pharmaceutical giant sells its entire 11.7% stake in the company.

AbelZeta will receive up to USD630 million from AstraZeneca, with the payment structure including both upfront cash and milestone fees tied to the GPC3 program’s progress in China.

The company recently filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its first BFS-based prefilled injection device, achieving a major regulatory breakthrough for the platform.

The company plans to develop the first phase of this facility on a 10,000 square metre site with an initial investment of RO 15 million (USD39 million).

Penumbra shareholders will have the option to receive either USD374 in cash or 3.8721 Boston Scientific shares, with the transaction structured as approximately 73% cash and 27% stock.

The company plans to bring Neopak Glass Prefillable Syringe production to its long-established facility in Columbus, Nebraska.

This partnership will fund the construction of a nine-bed NICU and an eight-bed PICU, along with consultation rooms, a pharmacy, and other essential areas.

Caldera raised USD75 million in a Series A financing round led by Atlas Venture, LAV, and venBio, followed by an additional USD37.5 million in a Series A-1 round led by Omega Funds.

The laboratory serves as the country’s primary reference centre for sophisticated testing, disease investigation, genetic analysis, and quality control across all health facilities.

This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.